breast-cancer
Using cancer spheroid-3D matrix models, scRNA-seq, and human tissue explants, researchers overturned the dogma that amoeboid cancer cells bypass the need for proteinases. CRISPR/Cas9 deletion of MMP14 abolished tissue-invasive activity in both mesenchymal and amoeboid modes. MMP14-deleted cells…
colorectal-cancer
New sulfonamide-Schiff base compounds (3a-d) showed significant anticancer activity against DLD-1 and HT-29 CRC cell lines with no toxicity to normal CCD-18Co cells. Compound 3c was most potent in DLD-1 (IC50=3.94 µM) and 3b in HT-29 (IC50=3.26 µM). Multi-mechanism activity: apoptosis induction,…
pancreatic-cancer
Single-cell transcriptomics + functional TCR characterization in murine pancreatic cancer found substantial diversity of tumor-reactive TCR clonotypes. Most reactive TCRs recognized syngeneic tumors across tissue types. Three T cell epitope classes were identified: a neoantigen, an endogenous…
breast-cancer
Mitocytosis expels damaged mitochondria via migrasomes, conferring resistance to mitochondria-targeted therapy. Researchers developed RH-NPs dual nanoplatform: TL/RH-NPs damage tumor mitochondria; CGT/RH-NPs block mitocytosis by inhibiting integrin signaling when cells attempt mitochondrial…
melanoma
Combining scRNA-seq and transcriptomics with PSO-SVM machine learning (particle swarm optimization + support vector machine), researchers identified 5 key SKCM metastasis-related genes: SFN, S100A8, KLF5, ARL4D, and TINCR. Expression differences were confirmed at single-cell level across different…
lung-cancer
Analysis of 421 SCLC patients at Karolinska using Bayesian and competing risk models: neutropenia during first-line treatment associated with better OS (HR 0.70). Higher etoposide dose linked to more AEs. Dose adjustment did not affect OS if patients completed 4 cycles. Male patients had fewer AEs…
breast-cancer
TNBC historically had few targeted options and the worst breast cancer outcomes. Recent advances include checkpoint inhibitors improving outcomes for PD-L1-positive metastatic disease, and ADCs (sacituzumab govitecan, trastuzumab deruxtecan) moving earlier in treatment algorithms. Molecular…
blood-cancer
Phase Ib study of TQB2618 (anti-TIM-3) + penpulimab (anti-PD-1) in 21 r/r cHL patients with prior PD-1/PD-L1 failure: 52% ORR (1 CR, 10 PR). TRAEs in 86%, grade ≥3 in 24%. Median duration of response and OS not reached at 14.1-month median follow-up.
lung-cancer
BDH2 overexpression in LUAD cell lines and xenograft mice significantly inhibited migration, invasion, and metastasis. Mechanism: BDH2 suppresses the Nrf2/HO-1 ferroptosis-resistance pathway, enhancing cancer cell sensitivity to ferroptotic death. Ferroptosis inhibitor Fer-1 reversed these effects,…
melanoma
A 70-year-old male with sinonasal mucosal melanoma progressed on nivolumab-ipilimumab (unresectable). After switching to nivolumab-relatlimab plus site-directed radiation, he achieved complete response after 8 cycles. Treatment interruption for suspected immune toxicity led to eventual progression.…
breast-cancer
New SOAT (SLC10A6) inhibitors (compounds 12 and 24) markedly reduced DHEAS uptake in MCF-7 breast cancer cells, decreasing intracellular estradiol synthesis and suppressing estrogen-dependent proliferation without cytotoxicity to normal cells. SOAT is an upstream regulator of intracrine estrogen…
blood-cancer
Phase 1 study of SAR445419 allogeneic NK cell therapy in 7 R/R AML patients (6 received treatment): no dose-limiting toxicities, two grade 2 infusion-related reactions (therapy-related). Five deaths, all from disease progression. No clinical responses observed. Study terminated early for strategic…
